JP7123921B2 - サブチラーゼサイトトキシンｂサブユニット変異体 - Google Patents

サブチラーゼサイトトキシンｂサブユニット変異体 Download PDF

Info

Publication number
JP7123921B2
JP7123921B2 JP2019524202A JP2019524202A JP7123921B2 JP 7123921 B2 JP7123921 B2 JP 7123921B2 JP 2019524202 A JP2019524202 A JP 2019524202A JP 2019524202 A JP2019524202 A JP 2019524202A JP 7123921 B2 JP7123921 B2 JP 7123921B2
Authority
JP
Japan
Prior art keywords
linked
fragment
variant
isolated protein
glycolylneuraminic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019524202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501521A (ja
JP2020501521A5 (enExample
Inventor
ポール ジェニングス，マイケル
デイ，クリストファー
ウェブスター パトン，アドリエンヌ
クリーランド パトン，ジェームス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016904572A external-priority patent/AU2016904572A0/en
Application filed by Griffith University filed Critical Griffith University
Publication of JP2020501521A publication Critical patent/JP2020501521A/ja
Publication of JP2020501521A5 publication Critical patent/JP2020501521A5/ja
Application granted granted Critical
Publication of JP7123921B2 publication Critical patent/JP7123921B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
JP2019524202A 2016-11-09 2017-11-09 サブチラーゼサイトトキシンｂサブユニット変異体 Active JP7123921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016904572A AU2016904572A0 (en) 2016-11-09 Subtilase cytotoxin b subunit mutant
AU2016904572 2016-11-09
PCT/AU2017/051230 WO2018085888A1 (en) 2016-11-09 2017-11-09 Subtilase cytotoxin b subunit mutant

Publications (3)

Publication Number Publication Date
JP2020501521A JP2020501521A (ja) 2020-01-23
JP2020501521A5 JP2020501521A5 (enExample) 2020-12-17
JP7123921B2 true JP7123921B2 (ja) 2022-08-23

Family

ID=62109062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019524202A Active JP7123921B2 (ja) 2016-11-09 2017-11-09 サブチラーゼサイトトキシンｂサブユニット変異体

Country Status (9)

Country Link
US (2) US11371033B2 (enExample)
EP (1) EP3538544B1 (enExample)
JP (1) JP7123921B2 (enExample)
KR (1) KR102703633B1 (enExample)
CN (1) CN110402251A (enExample)
AU (1) AU2017358401B2 (enExample)
CA (1) CA3044303A1 (enExample)
ES (1) ES2983352T3 (enExample)
WO (1) WO2018085888A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112760305B (zh) * 2021-01-25 2022-04-29 浙江工业大学 一种栖热腔菌磷酸酶突变体及其应用
CN117651868A (zh) * 2021-05-06 2024-03-05 伊诺维吉股份有限公司 与肿瘤源性胞外囊泡相关的方法
WO2022236383A1 (en) * 2021-05-14 2022-11-17 The University Of Adelaide Methods of analysing a sample

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006509727A (ja) 2002-08-02 2006-03-23 アンスティチュ、キュリー 腫瘍の診断およびｇｂ３発現腫瘍への薬物送達のためのベクターとしてのシガトキシンｂサブユニット
JP2014505064A (ja) 2011-01-26 2014-02-27 セニックス バイオサイエンス ゲーエムベーハー 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US7078489B2 (en) * 2003-12-22 2006-07-18 Adelaide Research & Innovation Pty, Ltd. Cytotoxin with a subtilase domain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006509727A (ja) 2002-08-02 2006-03-23 アンスティチュ、キュリー 腫瘍の診断およびｇｂ３発現腫瘍への薬物送達のためのベクターとしてのシガトキシンｂサブユニット
JP2014505064A (ja) 2011-01-26 2014-02-27 セニックス バイオサイエンス ゲーエムベーハー 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Byres, E. et al.，"Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin"，Nature，2008年，Vol. 456，pp. 648-652
Malykh, Y. N. et al.，"N-Glycolylneuraminic acid in human tumours"，Biochimie，2001年，Vol. 83，pp. 623-634
Paton, A. W. et al.，"A new family of potent AB(5) cytotoxins produced by Shiga toxigenic Escherichia coli"，J. Exp. Med.，2004年，Vol. 200，pp. 35-46

Also Published As

Publication number Publication date
JP2020501521A (ja) 2020-01-23
EP3538544B1 (en) 2024-03-27
EP3538544A4 (en) 2020-04-15
ES2983352T3 (es) 2024-10-22
CA3044303A1 (en) 2018-05-17
KR20190084995A (ko) 2019-07-17
EP3538544A1 (en) 2019-09-18
US20190367895A1 (en) 2019-12-05
US11371033B2 (en) 2022-06-28
AU2017358401B2 (en) 2022-01-13
AU2017358401A1 (en) 2019-05-30
US20220372459A1 (en) 2022-11-24
WO2018085888A1 (en) 2018-05-17
KR102703633B1 (ko) 2024-09-05
CN110402251A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
JP7479435B2 (ja) 癌治療および判断ターゲットとしてのｌｙ７５
ES2677367T3 (es) Anticuerpos anti-Axl y usos de los mismos
US20240002422A1 (en) Glycan Analysis and Profiling
JP6359461B2 (ja) Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤
US20220372459A1 (en) Subtilase cytotoxin b subunit mutant
KR20140071501A (ko) Ｓｐａｒｃ 결합 ｓｃｆｖｓ
CA2853637A1 (en) Anti-canine cd20 monoclonal antibodies and methods of use
KR20150119164A (ko) Dll3 결합 시약을 포함하는 암에 대한 치료적 및 진단적 타겟
JP6617110B2 (ja) 遺伝子組換えカイコにより生産したビオチン化酸化ｌｄｌ受容体・終末糖化産物受容体
WO2015016267A1 (ja) 抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
US10179166B2 (en) Ehrlichial invasin for immunization, diagnosis, and cell delivery
WO2014178196A1 (ja) シアリル化糖鎖を認識するモノクローナル抗体
US20220003777A1 (en) Methods Employing Mucin-Specific Proteases
US20180177842A1 (en) Immune system modulators and compositions
KR20230077720A (ko) Mucin-1에 특이적인 항체 및 이의 사용 방법
KR101256181B1 (ko) 톡소포자충 항원을 포함하는 융합 단백질 및 이를 포함하는 진단 키트
KR102244121B1 (ko) 브루셀라균의 omp28에 특이적으로 결합하는 단일클론항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도
ES2712736T3 (es) Anticuerpos anti-Axl y sus usos
AU2006248789A1 (en) PSK- I and its modulators for the treatment/diagnosis of cancer
WO2000052470A1 (fr) Moyen de diagnostic et de traitement de la leucemie
AU2005238281A1 (en) A protein involved in cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210811

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220810

R150 Certificate of patent or registration of utility model

Ref document number: 7123921

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250